Paper of the Month - September, 2015

0 rating

Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS.

Kappos L, Radue EW, Comi G et al.
Natalizumab and fingolimod are disease-modifying therapies in relapsing–remitting multiple sclerosis (RRMS). Natalizumab treatment can be discontinued because of disease breakthrough, JC virus positivity and thereby the risk of developing progressive multifocal leukoencephalopathy (PML), patient preference for oral therapies, persistent anti-natalizumab antibodies, or poor tolerability.


READER POLL

MS Poll 1
Which of the following do you think is the most important risk factor for MS?






Powered by NetPolls

WEB LINKS

SUBMIT AN ARTICLE